NEWS

Bio-Gate improves cost structure in the first half of 2014

• All relevant expense items decreased • Revenue falls to EUR 1.1 million owing to one-time effect in the case of antibacterial additives • Half-year result nearly stable Nuremberg, September 11, 2014 — In the first six months of fiscal year 2014, Bio-Gate AG (ISIN DE000BGAG981), a leading supplier of antimicrobial products and multifunctional surfaces for medical technology, built on the positive operational trend of the second half of 2013. Existing projects were successfully continued and new customers acquired in all business divisions. However, the revenue trend in the first half of the year was influenced by a one-time effect, resulting in a decline in income by around 20% to EUR 1.1 million (PY: EUR 1.4 million) despite the positive operational trend. This was due to changes in the sales organization of a customer in the area of antibacterial additives. This caused delays, and the delivery of the agreed sales volumes will not start until the second half of the year. Moreover, the exceedingly strong first half of prior year 2013, in which nearly 60% of the entire annual income was realized through catch-up effects, distorted the comparison. Consequently, 2014 mid-year revenue increased by around six percent over the second half of 2013. Through the markedly improved cost structure in the Bio-Gate Group, the mid-year result remained nearly stable at EUR -0.8 million (PY: EUR -0.8 million). Cosmetics business remains the strongest revenue driver Bio-Gate realized marked growth in the case of MicroSilver-based cosmetics products that were developed for customers and already exceeded the entire previous year’s revenues in the first half year of 2014. The company registered equally...

Bio-Gate AG gains additional international distribution partner in the area of antibacterial additives

• New sales markets created for MicroSilver • Growth with global partners continued • First contributions to sales already expected in current business year Nuremberg, July 15, 2014 – Bio-Gate AG (ISIN DE000BGAG981), a leading supplier of antimicrobial products and multifunctional surfaces for medical technology, continues with international expansion for MicroSilver through well-known distribution partners. The new joint efforts primarily involve the regions of South and Latin America as well as Bulgaria and Greece. The new distribution partners for Bio-Gate’s MicroSilver include the Mexican distributor SUANFARMA, which supplies raw materials and finished products for the pharmaceuticals, nutrition, veterinary, biotechnology and cosmetics sectors. SUANFARMA has branches in over 60 countries – on all five continents. Bio-Gate also acquired additional national partners in Bulgaria and Greece. Bio-Gate already expects initial contributions to sales in the 2014 business year from these joint efforts. Furthermore, Bio-Gate has signed a letter of intent for a distribution partnership in the area of antibacterial additives with a global distributor of special chemicals for life science and industrial applications. The plan is for the wholesaler to distribute Bio-Gate’s MicroSilver to pharmaceutical and industrial enterprises in France, the Benelux countries, Ireland and Great Britain. The distributor has a network of 20,000 customers and also has a great deal of expertise in the pharmaceutical and industrial target sectors. The company expects to sign the final contract soon. Karl Richter, CEO of Bio-Gate AG, explains: “With these new distribution partners, we are continuing with our strategy of growing globally with distributors and direct customers in all the markets that are relevant for us. After Europe and North America, we are...

In fiscal year 2013, Bio-Gate AG lays the foundation for continued growth

• Revenue rose by about 10 percent in fiscal year 2013, to almost 2.5 million euros; the deficit was significantly reduced, to about 1.5 million euros • Liabilities were significantly reduced; equity capital ratio reaches 50.3 percent • Successful financial and accounting restructuring creates conditions for continued growth Nuremberg, April 3, 2014 – Bio-Gate AG (ISIN DE000BGAG981), a leading supplier of antimicrobial and multifunctional surfaces for medical technology, achieved its essential financial objectives in fiscal year 2013. As was already reported with the interim figures in late February, the company increased revenue and reduced its losses. It is expected that this positive development will continue in 2014: Management expects that, given increasing revenues and a decreasing deficit, the break-even point (EBITDA) at the operational level can be reached by the end of the year. The good operational development of Bio-Gate AG in the 2013 reporting year is reflected in all significant financial key figures. For example, revenues rose by almost ten percent, to 2,484 thousand euros (previous year: 2,269 thousand euros). At the same time, costs in important areas were further reduced: Because of slightly decreased employee numbers, personnel expenses fell by 7.0 percent to 1,703 thousand euros (previous year: 1,831 thousand euros), and other operational expenses decreased by 24.4 percent to 1,449 thousand euros (previous year: 1,916 thousand euros). In this regard, costs were also incurred for unexpected repairs, maintenance and financial services in the previous year. Overall, the EBITDA improved to -1,125 thousand euros (previous year: -1,747 thousand euros). The group’s deficit fell was reduced as planned to -1,544 thousand euros (previous year: -2,158 thousand euros). This...

Bio-Gate AG anticipates considerable growth in 2014

    According to preliminary figures, revenue for the entire year 2013 rose by about 10 percent to around EUR 2.5 million, with the deficit considerably decreased to around EUR 1.5 million     Financial and balance-sheet restructuring successfully implemented, equity capital ratio at 50.4 percent     Coating order for animal implants received Nuremberg, February 26, 2014 — Bio-Gate AG (ISIN DE000BGAG981), a leading supplier of antimicrobial products and multifunctional surfaces for medical technology, made great strides at the operational level in fiscal year 2013, achieved the forecasts for revenue and consolidated operating results and, in addition, successfully completed financial and balance-sheet restructuring. This positive trend is expected to continue in 2014: The company expects increasing revenues and an improved operating result. Additional projects were acquired in all divisions in 2013, all of which are now in the development phase or in production or will go into production in 2015. Bio-Gate has had a gratifying start to new fiscal year 2014. After successfully completing preclinical studies last year on the coating of artificial joints and implants in the field of medical technology products for animals, 2014 got off to a good start with the order for coating stainless steel implants. The customer is also interested in antibacterial sprays and creams for wound treatment in animals. In addition, work started on further development projects and existing projects advanced according to plan. Improved revenues and operating result The business of Bio-Gate AG proceeded gratifyingly in fiscal year 2013. According to preliminary figures, consolidated revenues rose by nearly ten percent to EUR 2.5 million, after being just under EUR 2.3 million in the previous...

Bio-Gate strengthens capital base

Nuremberg, February 13, 2014 – Bio-Gate AG (ISIN DE000BGAG999), a leading supplier of antimicrobial products and multifunctional surfaces for medical technology, has made use of the authorization obtained at the shareholders’ meeting of August 22, 2013 and successfully completed the placement of a zero-coupon convertible bond. A total of 156,972 bearer convertible debentures—with the exclusion of preemptive rights—were subscribed by anchor shareholders at a price of 1.50 euros each. The company thereby realized gross proceeds of approximately EUR 0.24 million from the placement of this issue. The non-interest-bearing convertible bond may be converted to shares of Bio-Gate AG at a ratio of 1:1 in specific exercise periods during the roughly three-year term. In case of non-conversion, full repayment will be made at the end of the term. VEM Aktienbank AG assisted with the transaction. Bio-Gate AG will release preliminary sales and earnings figures for fiscal year 2013 at the end of February. The annual report is expected to be published in April. Contact: Cortent Kommunikation AG Gerd Rückel/Christian Dose Tel: +49 (0)69 / 57 70 300 – 61 presse@bio-gate.de Bio-Gate AG Neumeyerstr. 28-34 D-90411 Nürnberg www.bio-gate.de Press Release About Bio-Gate: The medical technology company Bio-Gate AG develops and markets applications which exploit unique silver technology to help prevent infections and thus to improve health. Bio-Gate’s specialty is treating materials and surfaces that are used in all areas of daily life with pure silver, thus providing long-term and medically effective protection against bacteria, micro-organisms and other pathogens. Bio-Gate works in three fields to supply a variety of products that provide antimicrobial protection: material refinement, surface coating and testing the antimicrobial...